The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Novavax said Monday morning that the Food and Drug Administration was asking the company to run a new trial of its Covid-19 ...

Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...

You can reach Helen on Signal at hbranswell.01. Confusion over the Food and Drug Administration’s delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend when ...

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...